Latest Headlines
-
ADLM Releases Guidance To Help Healthcare Professionals Navigate Respiratory Virus Testing In A Post-COVID World
5/9/2024
The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) has issued a new guidance document that provides expert recommendations on fundamental areas of clinical testing for respiratory viral infections.
-
Indica Labs Receives First FDA Clearance For HALO AP Dx Digital Pathology Platform
5/8/2024
Indica Labs, the leading provider of digital pathology solutions, announced today that it received FDA clearance for HALO AP Dx, an enterprise digital pathology platform, for primary diagnosis.
-
Orchard Software Partners With Luxor Scientific To Expand Testing Services
5/8/2024
Orchard Software is pleased to announce its collaborative test-expansion partnership with Luxor Scientific Medical Laboratories.
-
Beckman Coulter And MeMed Extend Partnership Advancing Host Immune Response Diagnostics
5/7/2024
Beckman Coulter Diagnostics, a global leader in clinical diagnostics, and MeMed, a leader in the emerging field of advanced host-response technologies, today announced expansion of their host immune response diagnostics partnership.
-
QIAGEN Enhances Bioinformatics Workflows With New Secondary Analysis Solution For Oncology And Inherited Disease Applications
5/2/2024
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of QCI Secondary Analysis, a cloud-based software-as-a-services (SaaS) solution enabling high-throughput secondary analysis for use with any clinical next-generation sequencing (NGS) data.
-
Valar Labs Announces Validation Of First Histology-Based Test To Predict Response To BCG In Bladder Cancer
5/1/2024
Valar Labs, the developer of computational histology AI tests for predicting response to cancer therapies, announced new data today which is being presented on Saturday, May 4, 2024 at the 2024 Annual Meeting of the American Urological Association (AUA) as a podium presentation (PD30-03).
-
Concert Expands Diagnostic Benefit Program To Manage Laboratory Testing For Health Plans
5/1/2024
Concert has expanded its Diagnostic Benefit Program, formerly known as the Genetics Benefit Program, to provide payment and clinical policies and payment accuracy capabilities across routine and advanced laboratory testing, enabling health plans to provide their members with access to these important clinical services at lower total costs, the company announced today.
-
Quest Diagnostics To Acquire PathAI Diagnostics To Accelerate AI And Digital Pathology Adoption In Cancer Diagnosis; Forms Licensing Agreements With PathAI
5/1/2024
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases.
-
Lyric And Concert Expand Partnership To Deliver Laboratory Payment Accuracy Solution
5/1/2024
Lyric, an AI-first leader in payment accuracy, has expanded its partnership with Concert to deliver payment accuracy across a rapidly expanding set of advanced and routine laboratory tests, the companies announced today.
-
AdvaMed Statement On The Release Of FDA Rule On Laboratory-Developed Tests
4/29/2024
Today, AdvaMed, the Medtech Association, released the following statements from President and CEO Scott Whitaker and Zach Rothstein, Executive Director of AdvaMedDx, on FDA’s final rule for Laboratory Developed Tests (LDTs):